Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company based in Wilmette, Illinois, is leading the charge in developing innovative cancer therapeutics in the United States. The company's flagship product, Validive, is a clonidine hydrochloride mucobuccal tablet that is undergoing Phase 2b/3 clinical trials aimed at preventing chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. In addition to Validive, Monopar is dedicated to the development of Camsirubicin, MNPR-101, MNPR-101 RIT, and MNPR-202, all of which demonstrate promising potential in treating various types of cancer. The biopharmaceutical company has entered into collaborations with the Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore, to further advance its research and development initiatives. Founded in 2014, Monopar Therapeutics is leading the charge in innovative cancer therapies.
Monopar Therapeutics Inc.'s ticker is MNPR
The company's shares trade on the NASDAQ stock exchange
They are based in Wilmette, Illinois
There are 1-10 employees working at Monopar Therapeutics Inc.
It is https://www.monopartx.com/
Monopar Therapeutics Inc. is in the Healthcare sector
Monopar Therapeutics Inc. is in the Biotechnology industry
The following five companies are Monopar Therapeutics Inc.'s industry peers: